X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (9294) 9294
Publication (569) 569
Book Review (93) 93
Newsletter (55) 55
Book Chapter (21) 21
Dissertation (10) 10
Conference Proceeding (4) 4
Book / eBook (3) 3
Newspaper Article (2) 2
Data Set (1) 1
Magazine Article (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (6354) 6354
cisplatin (5528) 5528
oncology (4368) 4368
female (4129) 4129
index medicus (3518) 3518
male (3390) 3390
chemotherapy (3373) 3373
cancer (2916) 2916
animals (2637) 2637
middle aged (2594) 2594
cisplatin - administration & dosage (2398) 2398
aged (2361) 2361
adult (2160) 2160
pharmacology & pharmacy (1942) 1942
antineoplastic combined chemotherapy protocols - therapeutic use (1809) 1809
pharmacokinetics (1493) 1493
cisplatin - pharmacokinetics (1410) 1410
mice (1193) 1193
treatment outcome (1171) 1171
antineoplastic agents - pharmacokinetics (1080) 1080
antineoplastic agents - administration & dosage (1041) 1041
carboplatin (1038) 1038
cisplatin - pharmacology (1037) 1037
antineoplastic agents - pharmacology (979) 979
cell line, tumor (963) 963
lung neoplasms - drug therapy (951) 951
antineoplastic combined chemotherapy protocols - adverse effects (940) 940
cisplatin - adverse effects (938) 938
dose-response relationship, drug (923) 923
antineoplastic agents - therapeutic use (918) 918
toxicity (892) 892
care and treatment (890) 890
cisplatin - therapeutic use (882) 882
medicine & public health (880) 880
paclitaxel (838) 838
neoplasms - drug therapy (832) 832
research (822) 822
rats (820) 820
carcinoma (804) 804
platinum (785) 785
antineoplastic agents - adverse effects (717) 717
analysis (716) 716
therapy (716) 716
antineoplastic agents (715) 715
ovarian neoplasms - drug therapy (711) 711
tumors (703) 703
drug administration schedule (702) 702
apoptosis (701) 701
antimitotic agents (646) 646
carcinoma, non-small-cell lung - drug therapy (640) 640
trial (636) 636
antineoplastic combined chemotherapy protocols - administration & dosage (616) 616
drug therapy (591) 591
drugs (576) 576
combined modality therapy (568) 568
ovarian cancer (551) 551
combination (546) 546
cisplatin - toxicity (534) 534
aged, 80 and over (519) 519
health aspects (515) 515
carboplatin - administration & dosage (512) 512
cytotoxicity (512) 512
doxorubicin (511) 511
pharmacology/toxicology (505) 505
neoplasm staging (504) 504
gemcitabine (499) 499
cancer therapies (495) 495
cell lung-cancer (492) 492
paclitaxel - administration & dosage (491) 491
deoxycytidine - analogs & derivatives (488) 488
surgery (473) 473
survival rate (455) 455
lung cancer (450) 450
phase-ii (446) 446
biochemistry & molecular biology (443) 443
infusions, intravenous (442) 442
5-fluorouracil (441) 441
tissue distribution (440) 440
lung neoplasms - pathology (439) 439
nephrotoxicity (434) 434
in-vitro (433) 433
article (432) 432
metastasis (430) 430
survival (428) 428
cancer research (427) 427
time factors (425) 425
expression (424) 424
oxaliplatin (420) 420
antineoplastic combined chemotherapy protocols - pharmacokinetics (405) 405
survival analysis (405) 405
fluorouracil - administration & dosage (401) 401
prognosis (400) 400
phase-i (395) 395
clinical trials (391) 391
deoxycytidine - administration & dosage (389) 389
antineoplastic agents - chemistry (388) 388
drug resistance, neoplasm (385) 385
cell survival - drug effects (384) 384
disease-free survival (384) 384
apoptosis - drug effects (380) 380
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (9027) 9027
Japanese (207) 207
French (60) 60
Chinese (28) 28
German (20) 20
Russian (15) 15
Spanish (8) 8
Korean (6) 6
Polish (4) 4
Italian (3) 3
Czech (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Molecular Pharmaceutics, ISSN 1543-8384, 08/2008, Volume 5, Issue 4, pp. 496 - 504
Journal Article
Drugs, ISSN 0012-6667, 06/2000, Volume 59, Issue 6, pp. 1261 - 1277
Neuroblastoma represents one of the most challenging malignancies for treatment decisions because of its unusual biological behaviour. The features include... 
Melphalan, pharmacokinetics | Topoisomerase inhibitors, therapeutic use | Cytarabine, pharmacokinetics | Teniposide, therapeutic use | Fluorouracil, pharmacokinetics | Research and development | Thioguanine, pharmacokinetics | Hydroxycarbamide, pharmacokinetics | Etoposide, pharmacokinetics | Vincristine, pharmacokinetics | Thiotepa, pharmacokinetics | Cisplatin, pharmacokinetics | Doxorubicin, pharmacokinetics | Zilascorb, pharmacokinetics | Procarbazine, pharmacokinetics | Cyclophosphamide, pharmacokinetics | Antineoplastics, therapeutic use | Bleomycin, pharmacokinetics | Busulfan, pharmacokinetics | Dacarbazine, therapeutic use | Ifosfamide, pharmacokinetics | Vinblastine, therapeutic use | Dactinomycin, pharmacokinetics | Lomustine, pharmacokinetics | Mercaptopurine, pharmacokinetics | Carboplatin, pharmacokinetics | Mitoxantrone, pharmacokinetics | Neuroblastoma, treatment | Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | NEURO-BLASTOMA | BONE-MARROW TRANSPLANTATION | MESSENGER-RNA | CHROMOSOME 1P | PEDIATRIC-ONCOLOGY-GROUP | METASTATIC NEUROBLASTOMA | CHILDHOOD NEUROBLASTOMA | CLINICAL RELEVANCE | GENE AMPLIFICATION | PHARMACOLOGY & PHARMACY | TOXICOLOGY | MULTIDRUG-RESISTANCE | Prognosis | Humans | Neuroblastoma - drug therapy | Hematopoietic Stem Cell Transplantation | Drug Resistance, Neoplasm | Transplantation, Autologous | Neuroblastoma - mortality
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 4/2014, Volume 73, Issue 4, pp. 737 - 747
The aim of this study was to characterize trastuzumab population pharmacokinetics (PKs) in patients with human epidermal growth factor receptor 2-positive... 
Population pharmacokinetics | Gastroesophageal junction cancer | Medicine & Public Health | Exposure–response | Oncology | Cancer Research | Pharmacology/Toxicology | Gastric cancer | Trastuzumab | Exposure-response | SURVIVAL | EGF | RECEPTOR | HER-2 | AMPLIFICATION | GENE | ONCOLOGY | PHARMACOLOGY & PHARMACY | rastuzumab | Receptor, ErbB-2 - genetics | Capecitabine | Esophageal Neoplasms - blood | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Receptor, ErbB-2 - metabolism | Stomach Neoplasms - metabolism | Male | Stomach Neoplasms - pathology | Cisplatin - administration & dosage | Esophageal Neoplasms - pathology | Young Adult | Antibodies, Monoclonal, Humanized - administration & dosage | Fluorouracil - administration & dosage | Antibodies, Monoclonal, Humanized - pharmacokinetics | Antibodies, Monoclonal, Humanized - blood | Esophageal Neoplasms - metabolism | Aged, 80 and over | Adult | Female | Fluorouracil - analogs & derivatives | Deoxycytidine - administration & dosage | Esophagogastric Junction - metabolism | Esophagogastric Junction - pathology | Stomach Neoplasms - drug therapy | Stomach Neoplasms - blood | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged | Esophageal Neoplasms - drug therapy | Deoxycytidine - analogs & derivatives | Antimitotic agents | Care and treatment | Chemotherapy | Epidermal growth factor | Analysis | Antineoplastic agents | Cancer
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 05/2015, Volume 205, pp. 89 - 97
Platinum-based polymeric nano-drugs, especially cisplatin-loaded polymeric nanoparticles (CDDP-NPs), have been extensively exploited for the treatment of solid... 
Glutamic acid | Pharmacokinetics | Nanoparticle | Biodistribution | Cisplatin | SOLID TUMORS | DRUG-DELIVERY | ANTICANCER DRUG | CANCER | CHEMISTRY, MULTIDISCIPLINARY | ENHANCED PERMEABILITY | CO-DELIVERY | INCORPORATED POLYMERIC MICELLES | PLGA-MPEG NANOPARTICLES | PHARMACOLOGY & PHARMACY | ANTITUMOR EFFICACY | TARGETED DELIVERY | Injections, Intravenous | Molecular Weight | Cisplatin - pharmacokinetics | Area Under Curve | Colonic Neoplasms - drug therapy | Male | Metabolic Clearance Rate | Polyethylene Glycols - chemistry | Antineoplastic Agents - administration & dosage | Colonic Neoplasms - metabolism | Cisplatin - administration & dosage | Drug Carriers | Nanoparticles | Polyglutamic Acid - analogs & derivatives | Tissue Distribution | Cisplatin - chemistry | Cisplatin - blood | Female | Antineoplastic Agents - pharmacokinetics | Nanomedicine | Mice, Inbred C57BL | Technology, Pharmaceutical - methods | Antineoplastic Agents - chemistry | Carcinoma, Lewis Lung - metabolism | Rats, Sprague-Dawley | Chemistry, Pharmaceutical | Carcinoma, Lewis Lung - drug therapy | Particle Size | Polyglutamic Acid - chemistry | Animals | Tumor Burden - drug effects | Colonic Neoplasms - pathology | Antineoplastic Agents - blood | Carcinoma, Lewis Lung - pathology | Mice | Mice, Inbred BALB C | Antimitotic agents | Ethylene glycol | Chemical plants | Analysis | Amino acids | Glutamate | Antineoplastic agents | Tumors
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 12/2002, Volume 94, Issue 24, pp. 1883 - 1888
The prescribed dose of anticancer agents is most commonly calculated using body surface area as the only independent variable, and it has been shown that this... 
TOPOISOMERASE-I INHIBITOR | INTRAVENOUS CISPLATIN | DOSE-ESCALATION | ADVANCED SOLID TUMORS | ONCOLOGY | ORAL TOPOTECAN | MATRIX-METALLOPROTEINASE INHIBITOR | SCHEDULE | CLINICAL PHARMACOKINETICS | PHASE-I | CREMOPHOR EL | Cytosine - analogs & derivatives | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Drugs, Investigational - pharmacokinetics | Cytosine - administration & dosage | Male | Paclitaxel - pharmacokinetics | Antineoplastic Agents - administration & dosage | Dose-Response Relationship, Drug | Fluorouracil - administration & dosage | Uracil - administration & dosage | Dacarbazine - analogs & derivatives | Adult | Dacarbazine - pharmacokinetics | Dioxolanes - pharmacokinetics | Female | Antineoplastic Agents - pharmacokinetics | Retrospective Studies | Body Surface Area | Paclitaxel - administration & dosage | Dacarbazine - administration & dosage | Cytosine - pharmacokinetics | Drug Administration Schedule | Docosahexaenoic Acids - administration & dosage | Docosahexaenoic Acids - pharmacokinetics | Drugs, Investigational - administration & dosage | Dioxolanes - administration & dosage | Infusions, Intravenous | Temozolomide | Fluorouracil - pharmacokinetics | Uracil - pharmacokinetics | Clinical Trials, Phase I as Topic | Uracil - analogs & derivatives | Antimitotic agents | Drug metabolism | Dosage and administration | Testolactone | Antineoplastic agents | Analysis
Journal Article
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2013, Volume 31, Issue 27, pp. 3327 - 3334
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 04/2000, Volume 6, Issue 4, pp. 1205 - 1218
Journal Article
European Journal of Cancer, ISSN 0959-8049, 11/2017, Volume 86, pp. 186 - 196
The phosphatidylinositol 3-kinase (PI3K) pathway is a potential therapeutic target in non–small cell lung cancer (NSCLC). This study aimed to evaluate the... 
First-line NSCLC | Metastatic NSCLC | Non–small cell lung | Paclitaxel | Carboplatin | Phosphatidylinositol 3-kinase | Pemetrexed | Cisplatin | Bevacizumab | Front-line NSCLC | SUBTYPES | PI3K INHIBITORS | KINASE | SENSITIVITY | OPPORTUNITIES | LESSONS | GDC-0941 | POTENT | ONCOLOGY | PRECLINICAL MODELS | PATHWAY | Non-small cell lung | Lung Neoplasms - drug therapy | Bevacizumab - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Phosphatidylinositol 3-Kinases - metabolism | Indazoles - administration & dosage | Protein Kinase Inhibitors - adverse effects | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Cisplatin - administration & dosage | Carboplatin - adverse effects | Drug Dosage Calculations | Aged, 80 and over | Adult | Female | Paclitaxel - administration & dosage | Carcinoma, Non-Small-Cell Lung - pathology | Protein Kinase Inhibitors - pharmacokinetics | Lung Neoplasms - enzymology | Bevacizumab - administration & dosage | Drug Administration Schedule | Carboplatin - administration & dosage | Paclitaxel - adverse effects | Treatment Outcome | Sulfonamides - pharmacokinetics | Protein Kinase Inhibitors - administration & dosage | Indazoles - pharmacokinetics | Pemetrexed - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cisplatin - adverse effects | Pemetrexed - administration & dosage | Sulfonamides - adverse effects | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Indazoles - adverse effects | Neoplasm Staging | Sulfonamides - administration & dosage | Antimitotic agents | Care and treatment | Safety and security measures | Lung cancer, Small cell | Metastasis | Lung cancer, Non-small cell | Antineoplastic agents
Journal Article
Journal Article
Journal Article
Expert Opinion on Drug Delivery, ISSN 1742-5247, 06/2017, Volume 14, Issue 6, pp. 745 - 753
Journal Article